Moderna to Reveal Long-Term Efficacy Data for Respiratory Vaccines
Cambridge, Tuesday, 7 April 2026.
This April, Moderna will present late-breaking revaccination data for its flu and RSV vaccines, a critical step toward proving long-term efficacy in the competitive seasonal immunization market.
Evaluating the Durability of mRNA-1010
On April 6, 2026, Moderna, Inc. (NASDAQ: MRNA) announced that it will deliver late-breaking oral presentations at the ESCMID Global Congress in Munich, Germany, scheduled to run from April 17 to April 21, 2026 [1]. A focal point of the upcoming presentations is mRNA-1010, the company’s investigational seasonal influenza vaccine [1]. Moderna plans to share a post-hoc analysis examining safety and immunogenicity in adults aged 50 and older [1]. This specific cohort received prior influenza vaccination—either with mRNA-1010 or a licensed egg-based alternative—with a median interval of 23 months between doses [1].
Expanding RSV Protection with mRESVIA
In addition to influenza, Moderna is advancing its respiratory syncytial virus (RSV) portfolio with mRESVIA, also known as mRNA-1345 [1]. The ESCMID presentation will feature interim results from an ongoing Phase 3 study evaluating mRESVIA as a heterologous revaccination dose [1]. This study specifically targets adults aged 60 and older who received the mRESVIA dose more than 12 months after a primary vaccination with a licensed RSV protein-based vaccine [1]. Establishing the efficacy of sequential administration is a vital metric for healthcare providers determining long-term immunization schedules [GPT].
Market Implications and Strategic Outlook
The impending data release arrives at a pivotal time for Moderna’s market valuation. Just days prior to the announcement, on April 2, 2026, Moderna’s stock experienced intra-day fluctuations on the Xetra exchange, trading in a range between 42.045 and 42.600, representing a variance of approximately 1.32 percent [2]. By demonstrating the durability and safety of revaccination for both influenza and RSV, the biotechnology firm aims to bolster investor confidence and validate its broader mRNA technology platform beyond its initial COVID-19 successes [GPT]. As the company plans further regulatory submissions in additional countries throughout 2026, the forthcoming presentations in Munich will likely serve as a crucial catalyst for its respiratory vaccine franchise [1].